Dataset Information

Duodenal inflammation in common variable immunodeficiency has altered transcriptional response to viruses

ABSTRACT: A substantial proportion of common variable immunodeficiency (CVID) patients has duodenal inflammation of largely unknown etiology. However, because of its histologic similarities with celiac disease, gluten sensitivity has been proposed as a potential mechanism. We aimed to elucidate the role of the duodenal microenvironment in the pathogenesis of duodenal inflammation in CVID by investigating the transcriptional, proteomic, and microbial signatures of duodenal biopsy samples in CVID.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Duodenal Mucosa

DISEASE(S): Duodenum Disease

SUBMITTER: Animesh Sharma

LAB HEAD: Mirta Mittelstedt Leal de Sousa

PROVIDER: PXD063461 | Pride | 2025-04-29

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 38

Publications

Duodenal inflammation in common variable immunodeficiency has altered transcriptional response to viruses.

Kaarbø Mari M Yang Mingyi M Hov Johannes R JR Holm Kristian K de Sousa Mirta Mittelstedt Leal MML Macpherson Magnhild E ME Reims Henrik M HM Kran Anne-Marte Bakken AB Halvorsen Bente B Karlsen Tom H TH Aukrust Pål P Lundin Knut E A KEA Fevang Børre B Bjørås Magnar M Jørgensen Silje Fjellgård SF

The Journal of allergy and clinical immunology 20221008 3

<h4>Background</h4>A substantial proportion of common variable immunodeficiency (CVID) patients has duodenal inflammation of largely unknown etiology. However, because of its histologic similarities with celiac disease, gluten sensitivity has been proposed as a potential mechanism.<h4>Objective</h4>We aimed to elucidate the role of the duodenal microenvironment in the pathogenesis of duodenal inflammation in CVID by investigating the transcriptional, proteomic, and microbial signatures of duoden ...[more]

PMID: 36220400

Similar Datasets

Project description:AML is a molecularly heterogenous disease that harbors multiple genomic, epigenomic, and transcriptomic abnormalities. Despite the use of newer therapeutic agents and identification of multiple prognostic markers, most patients with AML still relapse or succumb to their disease. Therefore, understanding biological factors especially at protein level that determine relapse is of major clinical interest in AML. Few studies have examined the global proteome in AML. Therefore, we have developed an integrated approach utilizing mass spectrometry-based proteomics and leveraging next generation RNA sequencing (RNAseq) to identify novel protein biomarkers associated with clinical outcome in a homogeneous population of undifferentiated viable leukemic blasts (uVLBs) from AML patients (Discovery cohort, n=27). Analyses identified 6761 unique proteins, with 238 and 460 proteins significantly associated with complete response (CR) and overall survival (OS), respectively. There was modest overlap between the prognostically significant transcript and protein biomarkers. We also were able to identify and quantify aberrant proteins arising from genomic mutations such as NPM1 and RUNX1. For validation of prognostic associations, TMT-based LC-MS/MS quantified protein expression across pooled patients from an independent patient cohort (validation cohort) and analyses examined the prognostic significance of the 238 proteins from the SWOG analyses associated with CR. Thirteen of the most promising candidates were significantly associated with CR prognosis, many of which are associated with cancer biology. Together, these studies show the feasibility and biological importance of examining the proteome in uVLBs. Studies examining for biomarkers in the proteome may be a powerful tool to uncover novel prognostic biomarkers that would otherwise not be identified by examining the genome or transcriptome. Furthermore, the multi-omics approach can be used to confirm the translation of potential neoantigens into actionable protein targets, which may lead to more cost-effective mechanisms for the development of innovative adoptive immunotherapies.

			Action	DRS
	20210309_CVID_1170.raw	Raw
	20210309_CVID_1180.raw	Raw
	20210309_CVID_1180_Again.raw	Raw
	20210309_CVID_1202.raw	Raw
	20210309_CVID_1340.raw	Raw